Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL96486 | 1.00 | HRH3 (0.56) | HRH3POLBMAPTALDH1A1KDM4E | |
| SCHEMBL1277016 | 0.98 | HRH3 (0.52) | HRH3POLBMAPTALDH1A1KDM4E | |
| SCHEMBL10103385 | 0.93 | HRH3 (0.61) | HRH3ALDH1A1L3MBTL1CYP2D6 | |
| SCHEMBL12712715 | 0.93 | — | — | |
| SCHEMBL20332771 | 0.92 | HRH3 (0.51) | HRH3POLBMAPTALDH1A1KCNH2 | |
| SCHEMBL21472087 | 0.91 | HRH3 (0.65) | HRH3ALDH1A1KCNH2CYP2D6 | |
| SCHEMBL10103384 | 0.91 | HRH3 (0.56) | HRH3MAPTALDH1A1L3MBTL1CYP2D6 | |
| SCHEMBL20332383 | 0.89 | HRH3 (0.49) | HRH3POLBMAPTALDH1A1KCNH2 | |
| SCHEMBL13849154 | 0.88 | HRH3 (0.61) | HRH3ALDH1A1KDM4EL3MBTL1CYP2D6 | |
| SCHEMBL10924619 | 0.87 | ALDH1A1 (0.39) | HRH3ALDH1A1KDM4ECYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023207101-A1 | IONIZABLE LIPID COMPOUNDS | Beijing Jitai Pharmaceutical Technology Co., Ltd. (CN) | 2023-11-02 | — | — | WO | disclosed |
| EP-4269385-A1 | IONIZABLE LIPID COMPOUNDS | Beijing Jitai Pharmaceutical Technology Co., Ltd. (CN) | 2023-11-01 | — | — | EP | disclosed |
| WO-2021145729-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-07-22 | — | — | WO | disclosed |
| US-9149463-B2 | Methods and compositions of treating a Flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150152064-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2015-06-04 | — | — | US | disclosed |
| US-8940730-B2 | Methods and compositions of treating a Flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2534134-A1 | LOW VISCOSITY IONIC LIQUIDS | Invista Technologies S.à.r.l. (CH) | 2012-12-19 | — | — | EP | disclosed |
| US-20120148534-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-06-14 | — | — | US | disclosed |
| WO-2011100232-A1 | LOW VISCOSITY IONIC LIQUIDS | INVISTA TECHNOLOGIES S.A R.L. (CH) | 2011-08-18 | — | — | WO | disclosed |
| EP-1654257-B1 | AMINOPYRONES AND THEIR USE AS ATM INHIBITORS | KUDOS PHARM LTD (GB) | 2010-03-17 | — | — | EP | disclosed |
| US-20100015093-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-01-21 | — | — | US | disclosed |
| US-7402583-B2 | Substituted quinolines as antitumor agents | ASTRZENCA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-7402583-B2 | Substituted quinolines as antitumor agents | ASTRZENCA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20070021407-A1 | Substituted quinolines as antitumor agents | ASTRAZENECA | 2007-01-25 | — | — | US | disclosed |
| US-20070021407-A1 | Substituted quinolines as antitumor agents | ASTRAZENECA | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021407-A1 | Substituted quinolines as antitumor agents | NR1H3, NR1H2, NR0B1 | HRH3 191/4885POLB 1952/4885MAPT 4728/4885 |
| US-20120148534-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | EIF2AK2, NSUN3, NSUN2 | HRH3 4193/4885POLB 582/4885MAPT 4569/4885 |
| US-20100015093-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | HRH3 4193/4885POLB 582/4885MAPT 4569/4885 |
| US-20150152064-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | EIF2AK2, NSUN3, NSUN2 | HRH3 4193/4885POLB 582/4885MAPT 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.